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Abstract
Children undergoing cardiac surgery often receive acetaminophen (paracetamol) as part of their postoperative pain treatment. To date, there is no
information on the pharmacokinetics (PK) of acetaminophen in this special population, even though differences, as a result of altered hemodynamics
and/or use of cardiopulmonary bypass,may be anticipated. Therefore, the aim of this study was to investigate the PK of intravenous acetaminophen in
children after cardiac surgery with cardiopulmonary bypass. In the study, both children with and without Down syndrome were included.A population
PK analysis, using NONMEM 7.2, was performed based on 161 concentrations of acetaminophen, acetaminophen sulfate, acetaminophen glucuronide,
and oxidative metabolites from 17 children with Down syndrome and 13 children without Down syndrome of a previously published study (median age,
177 days [range, 92–944], body weight, 6.1 kg [4.0–12.9]). All children received 3 intravenous acetaminophen doses of 7.5 mg/kg (<10 kg) or 15 mg/kg
(10 kg) at 8–hour intervals after cardiac surgery. For acetaminophen and its metabolites, 1-compartment models were identified. Clearance of
acetaminophen and metabolites increased linearly with body weight. Acetaminophen clearance in a typical child of 6.1 kg is 0.96 L/h and volume of
distribution 7.96 L.Down syndrome did not statistically significantly impact any of the PK parameters for acetaminophen, nor did any other remaining
covariate.When comparing the PK parameters of acetaminophen in children after cardiac surgery with cardiopulmonary bypass with those from chil-
dren of the same age following noncardiac surgery reported in the literature, clearance of acetaminophen was lower and volume of distribution higher.
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Congenital heart disease accounts for almost one-third
of all congenital defects.1 In many institutions around
the world, children routinely receive acetaminophen
(paracetamol) as part of their postoperative pain
treatment.2
Acetaminophen is metabolized in the liver by var-
ious metabolic pathways.3 In adults, acetaminophen
is mainly metabolized to acetaminophen glucuronide
(55%) and acetaminophen sulfate (30%).4–6 To a small
extent, acetaminophen is excreted unchanged in urine
(2%–5%). Metabolism by cytochrome P450 accounts
for 5% to 10% of the elimination, which is me-
diated primarily by cytochrome P450 2E1 to form
the toxic metabolite N-acetyl–p-benzoquinone inine
(NAPQI).4–8 Under normal conditions, NAPQI is im-
mediately neutralized by conjugationwith gluthatione.9
After formation of acetaminophen glutathione, both
acetaminophen cysteine and acetaminophen mercap-
turate are formed. However, at high dosages, glutha-
tione will be depleted and NAPQI can result in
hepatocellular necrosis.9
Several studies have reported on the pharmacokinet-
ics (PK) of acetaminophen in infants and children.10,11
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However, there are no reports on the PK of ac-
etaminophen in children after cardiac surgery with
cardiopulmonary bypass. There are several reasons why
children may have different PK after cardiac surgery
compared to noncardiac surgery.12,13 This can be as-
cribed not only to the altered hemodynamic situation
of those childrenwith cardiac anomalies, but also to the
perioperative use of cardiopulmonary bypass, which
has profound effects on the PK because of hemodi-
lution, hemodynamic changes, hypothermia, systemic
inflammatory response syndrome, and sequestration
of drugs in the cardiopulmonary bypass system.13,14
Additionally, as nearly half of children with Down
syndrome have a congenital heart defect,15 they rep-
resent a relatively large subgroup in the population
of children undergoing cardiac surgery. While differ-
ences in acetaminophen metabolism in adolescents and
adults with and without Down syndrome have been
suggested,16 this has not been studied in children.
Therefore, the aim of this study is to investigate the
PK of acetaminophen and its metabolites in children
after cardiac surgery with cardiopulmonary bypass.
For this purpose, in blood samples from a previously
published study on morphine PK and pharmacody-
namics after cardiac surgery in children with and with-
out Down syndrome17 acetaminophen concentrations
were measured and data analyzed in relation to ac-
etaminophen dosing information.
Methods
Patients, Study Design, and Drug Dosing
In this population PK study, blood samples on
acetaminophen and metabolite concentrations were
analyzed from a previously published prospective ob-
servational clinical study on analgesia and sedation
in 38 children with and without Down syndrome
who underwent cardiac surgery with cardiopulmonary
bypass.17 The study design has been described in detail
elsewhere17 and is summarized here as relevant for this
analysis. The study was conducted at the Department
of Anesthesia and Intensive Care Medicine of Our
Lady’s Children’s Hospital, Dublin, Ireland, following
approval by the ethical board of the hospital. Written
informed consent for the study was obtained from par-
ents preoperatively. Its primary aim was to compare the
PK and pharmacodynamics of morphine and midazo-
lam in children with and without Down syndrome after
cardiac surgery with cardiopulmonary bypass, while
intravenous acetaminophen was also administered to
most of the patients. In the initial study, inclusion crite-
ria for patients both with and without Down syndrome
were age 3 to 36 months and cardiac surgery with
cardiopulmonary bypass for atrial septal defect, ven-
tricular septal defect, atrioventricular septal defect or
Table 1. Characteristics of 30 Children Included in the Current Analysis
Variable
Children With
Down Syndrome
(n = 17)
Children Without
Down Syndrome
(n = 13) P Value
Male 7 (41) 6 (46) .79
Gestational age, weeks 39 [28–42] 39.3 [35.5–41.0] .16
Age at surgery, days 175 [105–944] 175 [92–300] .19
Weight at surgery, kg 6.1 [4.2–12.9] 5.7 [4.0–8.2] .18
Procedure <.001
AVSD 13 (76.5) 1 (7.7)
VSD 4 (23.5) 5 (38.5)
TOF 0 (0) 7 (53.9)
RACHS score <.001
2 4 (23.5) 12 (92.3)
3 13 (76.5) 1 (7.7)
CPB time, min 111 [51–168] 106 [61–105] .89
Aortic cross-clamp
time, min
74.5 [27–118] 66 [36–110] .98
Values are presented as median [range] or N (%) unless specified otherwise.
ASD, atrial septal defect; AVSD, atrioventricular septal defect; CPB, cardiopul-
monary bypass; RACHS, risk adjustment for congenital heart surgery; TOF,
tetralogy of Fallot; VSD, ventricular septal defect.
tetralogy of Fallot repair. An additional inclusion cri-
terion for the Down syndrome group was a diagnosis of
trisomy 21.
Postoperatively, intravenous acetaminophen, admin-
istered as an infusion over 15 minutes, was given 3 times
in a dose of 7.5 mg/kg (<10 kg) or 15 mg/kg (10 kg)
at 8-hour intervals according to the postoperative pain
protocol. Scavenge blood samples from the subgroup
receiving intravenous acetaminophen in the postopera-
tive setting were used for the current study (n= 17 with
Down syndrome; n = 13 without Down syndrome).
Figure S1 provides plots of the spread in sampling
times relative to the first paracetamol dose (Figure S1A)
and relative to time after the most recent dose (Figure
S1B). The number of samples in which acetaminophen
and metabolite concentrations were measured ranged
from 3 to 9 per patient. The PK model was based on
161 acetaminophen, 161 acetaminophen sulfate, 161 ac-
etaminophen glucuronide, 161 acetaminophen cysteine,
and 153 acetaminophen mercapturate concentrations.
The clinical characteristics of the included patients
(N = 30) are shown in Table 1.
Analytical Assay
Blood samples were centrifuged, and plasmawas stored
at –80°C for 2 years. Concentrations of acetaminophen
and its metabolites, glucuronide, sulphate, gluthatione,
cysteine, and mercapturate, were determined by ultra-
performance liquid chromatography and tandem mass
spectrometry at the hospital pharmacy, Erasmus Med-
ical Centre Rotterdam, The Netherlands.3
The assays were linear over 0.020 to 25.0 mg/L,
0.047 to 47.0 mg/L, and 0.043 to 43.0 mg/L for
acetaminophen, acetaminophen glucuronide, and
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acetaminophen sulfate, respectively, and over 0.022 to
43.0mg/L, 0.020 to 10.0mg/L, and 0.010 to 15mg/L for
acetaminophen gluthation, acetaminophen cysteine,
and acetaminophen mercapturate. The lower limit
of the ranges represents the lower limits of quanti-
fication (LLOQ). Intra- and interassay accuracies
ranged from 93.6% to 130.9%. Intra- and interassay
imprecision did not exceed 15%.3
Population PK Analysis and Internal Validation
Acetaminophen and metabolite concentrations were
analyzed using nonlinear mixed-effect modeling soft-
ware NONMEM version 7.2 (ICON Development So-
lutions, Ellicott City, Maryland) using the first-order
estimation method with the interaction option and
subroutine ADVAN13, TOL4. Pirana (version 2.9.2),
R (version 3.3.0), and PsNR© version (version 4.4.8)
software were used to process the runs and evaluate and
visualize the data.
Concentrations were expressed in acetaminophen
equivalents (mg/mL) via conversion based on mole-
cular weights (acetaminophen = 151.165 g/mol;
acetaminophen glucuronide = 349.271 g/mol; aceta-
minophen sulphate = 231.222 g/mol; acetaminophen
cysteine= 254.304 g/mol; acetaminophenmercapturate
= 296.341 g/mol).18–22 For acetaminophen, aceta-
minophen glucuronide, acetaminophen sulphate, and
acetaminophen cysteine, 3 samples (1.08 %) were
below LLOQ; and for acetaminophen mercapturate,
8 samples (4.88 %) were below LLOQ. These samples
were excluded from the analysis. All acetaminophen
glutathione concentrations were below LLOQ, and this
metabolite was therefore not included in the model.
The model-building process was performed in a
stepwise manner: (1) the structural model, (2) the
statistical model, (3) the covariate model, and (4) model
evaluation.23 Discrimination between submodels was
made by the likelihood ratio test using the objective
function value (OFV) (ie, –2 log likelihood), where a
decrease in OFV of 7.8 points (P < .005 based on
an assumed χ2 distribution) was considered as statisti-
cally significant, between nested models with 1 degree
of freedom. Furthermore, basic goodness-of-fit plots
were evaluated, as well as precision of the parameter
estimates and the condition number.
Structural and Statistical Model. One- and 2-
compartment PK models for acetaminophen and
its metabolites were tested. To investigate a possible
delay in metabolite formation, addition of transit
compartments was tested. As acetaminophen cysteine
and acetaminophen mercapturate are gluthation-
derived metabolites formed from the toxic NAPQI
metabolite, the sum of both metabolite concentrations
was modeled in 1 compartment, assuming the same
distribution volume for both metabolites.24
For the metabolite model to be identifiable, it was
assumed that the ratio of formation clearance of ac-
etaminophen sulfate and acetaminophen glucuronide
is the same in children between 3 and 9 years of
age—namely, a fraction of 0.49 and 0.36 of total
elimination acetaminophen clearance25—and that the
oxidative metabolites and the unchanged clearance
of acetaminophen are the same as in healthy adults,
namely, 0.10 and 0.05 of the total acetaminophen
clearance.4–6,26
Interindividual variability on the model parameters
was assumed to be log-normally distributed and tested
on all parameters. For the intraindividual variability
and residual unexplained variability, a proportional,
additive, and combined error model were tested.
Covariate Model. To evaluate the impact of growth
and maturation on PK processes, body weight and age
were tested as covariates. Additionally, tested covariates
included sex, Down syndrome, cardiopulmonary by-
pass, and risk adjustment for congenital heart surgery
(which quantifies the risk for in-hospital mortality for
pediatric patients undergoing cardiac surgery, with a
value of 1 indicating the lowest risk and 6 the highest27).
Continuous covariates were entered into the model
using a linear or power equation (Equation 1).
Pi = θ∗1
(
C OVi
C OVmedian
)θ3
+ θ2 (1)
In the equation, Pi represents the individual param-
eter estimates, θ1 and θ2 represent the typical parameter
estimates for the covariate relationship, and COVi rep-
resents the covariate value for the individual, which is
normalized by the median covariate value (COVmedian)
representing the median value of the covariate. θ3 is an
exponent fixed to 1 for a linear function or estimated for
a power function. For the categorical covariates, such as
Down syndrome and sex, the fractional change for one
group compared to the other group was calculated.
A data-driven covariate analysis was performed.
Potential covariates were entered separately into the
model and considered statistically significant when
OFV decreased with at least 7.8 points (P < .005).
When more than one significant covariate was identi-
fied, the covariate causing the largest drop in OFV was
retained in the model and additional covariates had to
reduce this OFV with the use of the same criteria to
be retained in the model. In addition, it was evaluated
whether the interindividual variability of the parameter
was reduced upon inclusion of the covariate and the
observations in the plot of eta versus covariate would
be randomly spread around zero.
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Figure 1. Schematic overview of the population pharmacokinetic model of acetaminophen (APAP) and its metabolites acetaminophen sulfate (sulf),
acetaminophen glucuronide (gluc), and the combined oxidative cysteine and mercapturate metabolites (ox). V indicates distribution volume for the
respective compounds,and CLE indicates the elimination clearance of the respective compound.Formation clearance of the metabolites and unchanged
elimination clearance were calculated as fixed fractions of the elimination clearance of acetaminophen.
Internal Validation
A normalized prediction distribution error (NPDE)
analysis was performed to evaluate the accuracy of the
predictions of the median trend and variability in con-
centrations of acetaminophen, acetaminophen sulfate,
acetaminophen glucuronide, and oxidative metabolites.
In order to perform this analysis, the original data set
was simulated 1000 times. Thereafter, each observed
concentration was compared to the simulated concen-
trations by using the NPDE package in R.28
Comparison With Noncardiac Surgery
The results obtained in our study were compared
to reported values for a similar population after
noncardiac surgery. For this, the study by Prins et al29
was used, as to the best of our knowledge this is the
only compartmental PK study using a similar popu-
lation after noncardiac surgery. This study included
26 patients between 6 months and 2 years of age
after craniofacial surgery. To illustrate the implication
of the differences in parameter values, PK profiles
for acetaminophen were generated upon a single dose
of 7.5 mg/kg intravenous infusion (administration in
15 minutes) in a typical patient (body weight, 6.1 kg)
after cardiac and noncardiac surgery.
Results
Population PK Analysis
Structural and Statistical Model. A 1-compartment
model for acetaminophen and a 1-compartment
model for acetaminophen sulfate, acetaminophen
glucuronide, and the oxidative metabolites best fitted
the data (Figure 1). Two-compartment models for the
distribution of acetaminophen and its metabolites did
not statistically significantly improve the model fit.
Interindividual variability could be identified for all
parameters. A proportional error model best described
residual variability for each of the compounds.
Covariate Model
In the covariate analysis, body weight was identified
as a significant covariate. It was included in a linear
relationship (Equation 1) on the total elimination clear-
ance of acetaminophen (CLEAPAP) and its metabolites
(CLEsulph, CLEgluc, CLEox). Including body weight in
an exponential instead of linear relationship on elim-
ination clearance of acetaminophen and its metabo-
lites did not further improve the model. As formation
of the metabolites is described as a fraction of the
elimination clearance of acetaminophen, the linear
relationship with body weight is perpetuated in these
parameters (see Methods). For volume of distribution
of acetaminophen, there was a trend toward a positive
correlation with body weight; however, this relationship
did not reach statistical significance probably because
it relied mostly on the presence of 3 individuals with
bodyweights outside the bodyweight range of the other
individuals (Figure S2). In addition, body weight in a
linear function on volume of distribution of the oxida-
tive metabolites significantly decreased OFV. However,
this covariate was not implemented, as the parame-
ter value could not be estimated accurately (relative
standard error [RSE], 161%) (Figure S2). No trends
between body weight and volume of distribution were
seen for acetaminophen sulfate and acetaminophen
glucuronide. Differences between patients with or with-
out Down syndrome were not observed at the various
stages throughout the covariate analysis. Inclusion of
any of the remaining covariates did not statistically
significantly improve the model fit. All parameter esti-
mates of the final model are shown in Table 2. From
this table it is apparent that the parameter values
could be accurately estimated (RSE generally 50%).
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Table 2. Population Pharmacokinetic Parameters of the Final Pharma-
cokinetic Model for Acetaminophen and Its Metabolites in Children
After Cardiac Surgery With Cardiopulmonary Bypass
Parameter
Final Model (RSE%)
[Shrinkage %]
Acetaminophen
VAPAP (L) 7.96 (10)
CLEAPAP = θ1 * (BW/6.1) + θ2
θ1 (L/h) 1.50 (27)
θ2 (L/h) –0.54 (61)
Acetaminophen sulfate
Vsulf (L) 0.68 (29)
CLEsulf = θ3 * (BW/6.1) + θ4
θ3 (L/h) 0.65 (19)
θ4 (L/h) –0.24 (35)
Acetaminophen glucuronide
Vgluc (L) 1.69 (29)
CLEgluc = θ5 * (BW/6.1) + θ6
θ5 (L/h) 1.41 (21)
θ6 (L/h) –0.53 (50)
Oxidative metabolites
Vox (L) 0.042 (18)
CLEox = θ7 * (BW/6.1) + θ8
7 (L/h) 40.86 (25)
8 (L/h) –1.26 (28)
Interindividual variability [ω2]
VAPAP 0.189 (27) [11]
CLEAPAP 0.185 (27) [6]
Vsulf 0.726 (52) [12]
CLEsulf 0.189 (32) [6]
Vgluc 0.927 (50) [15]
CLEgluc 0.129 (39) [13]
Vox 0.600 (49) [9]
CLEox 0.552 (32) [9]
Residual variability [σ2]
Proportional error for acetaminophen 0.146 (29) [9]
Proportional error for acetaminophen sulfate 0.0507 (15) [16]
Proportional error for acetaminophen
glucuronide
0.0813 (14) [15]
Proportional error for oxidative metabolites 0.0494 (12) [16]
See also Figure 1.
BW, body weight; CLEAPAP = CLfsulf + CLfgluc+ CLfox + ClfAPAP unchanged,
where CLfsulf is formation clearance of acetaminophen sulphate, CLfgluc is
formation clearance of acetaminophen glucuronide, and CLfox is formation
clearance of oxidative metabolites; CLEgluc, elimination clearance of ac-
etaminophen glucuronide;CLEox, elimination clearance oxidative metabolites;
CLEsulph, elimination clearance of acetaminophen sulfate; Vgluc, central volume
of distribution acetaminophen glucuronide;Vox,central volume of distribution
oxidative metabolites; Vpcm, central volume of distribution of acetaminophen;
Vsulf , central volume of distribution acetaminophen sulfate
Moreover, the residual variability was generally well
below 15%.
Figure 2 presents the plots of observed versus
population-predicted concentrations of acetamino-
phen and its metabolites. These plots show no bias
around the line of unity, indicating that themodel accu-
rately describes concentrations over the concentration
range (Figure 2A): this is the same for children with
andwithoutDown syndrome. Similarly, the conditional
weighted residuals over time after dose are unbiased for
both subpopulations (Figure 2B), indicating that con-
centrations predictions are accurate over the entire time
range.
Internal Model Validation
The NPDE distribution for acetaminophen and
metabolites are depicted in Figure S3. The histograms
of the NPDE follow a normal distribution. No trend
is observed in the NPDE vs time and the NPDE vs
predicted concentrations, confirming that the model
adequately quantifies both the median trend and the
variability in the observed concentrations.
Comparison With Noncardiac Surgery
For the typical child of 6.1 kg in our study, total
elimination clearance and distribution volume of ac-
etaminophen are 0.96 L/h and 7.96 L, respectively
(Table 2). Prins et al29 reported a clearance value of
1.04 L/h and 2-compartment distribution with volumes
of 0.69 L and 3.80 L of the central and peripheral
compartments, respectively, in the same typical child
(6.1 kg) after noncardiac surgery. Figure 3 shows
the population-predicted acetaminophen concentra-
tions after a single intravenous dose of 7.5 mg/kg
of acetaminophen over 15 minutes in this typical in-
dividual after both types of surgery. The maximum
concentration (Cmax) value for acetaminophen was 84%
lower after cardiac surgery compared to after non-
cardiac surgery. In addition, maximum concentration
shows a different shape of peak for the cardiac vs
noncardiac surgery group, due to the use of a 2-
compartment model to describe PK of acetaminophen
in the noncardiac surgery group. In addition, because
the clearance of acetaminophen was lower after cardiac
surgery compared to noncardiac surgery, the trough
level at 8 hours was more than a factor 50 higher in
this typical patient, compared to a typical patient after
noncardiac surgery.
Discussion
The present study investigated the PK of aceta-
minophen and its metabolites in children after car-
diac surgery with cardiopulmonary bypass, using a
population PK modeling approach. Contrary to a
previous report,16 no differences in PK parameters
were observed between children with or without Down
syndrome; therefore, these data were combined.
Although the study sample size may be considered
limited, the advantage of population PK modeling is
that all concentration-time data are analyzed together,
thereby enhancing the statistical power.12,29 Indeed,
the RSEs of the parameter estimates obtained in this
analysis show that these values could be obtained
with acceptable precision given the available data.
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Figure 3. Acetaminophen concentrations over time in a typical child of 6.1 kg upon a single intravenous dose of 7.5 mg/kg after cardiac surgery (solid
black line) and noncardiac surgery (dotted black line).
Furthermore, extensive model validation showed that
the model not only describes the obtained data well
(Figure 2) but also predicts the data well (Figure S3).
In our study, the clearance of acetaminophen and
metabolites was found to increase with body weight,
which was found to be a better descriptor of the impact
of maturational changes than age, which is in line with
other studies.30 However, it is important to mention
that the model was developed based on data from
children aged between 3 months and 3 years, with a
body weight ranging between 4.0 and 12.9 kg. As many
developmental changes occur in children younger and
older than this age range, extrapolation outside this
age range is not justified as the linear function in this
covariate relationship is only appropriate in the studied
age range.30
Due to differences in parameterization and covari-
ate relationships, direct comparisons between litera-
ture values are difficult; however, comparisons between
parameter values for typical individuals are possible.
A previous study on the PK of acetaminophen after
noncardiac surgery29 reported for a child weighing
6.1 kg a clearance value of 1.04 L/h, which is higher in
comparisonwith our estimate in post-cardiopulmonary
bypass cases (0.96 L/h). In our analysis, we identified a
1-compartment model, while in patients after noncar-
diac surgery 2 compartments were identified. Although
our analysis included observed concentrations shortly
after dosing (Figure S1), it is possible that this was
not sufficient to identify 2 compartments. Alternatively,
differences in the impact of the 2 surgery types on pa-
tients’ physiology may cause true differences in the dis-
tribution of acetaminophen. Either way, the combined
central and peripheral volume of distribution after
noncardiac surgery (4.49 L for a 6.1-kg child) was lower
in comparison with the total volume of distribution
found in our analysis in children after cardiac surgery
(7.96 L for a 6.1-kg child). The differences in clearance
and volume of distribution may be attributed to the
influence of cardiopulmonary bypass causing hemody-
namic changes and fluid shifts, while the occurrence
of inflammation or systemic inflammatory response
syndrome may also impact metabolic capacity.12,13
To allow for a further comparison of the differences
in the PK of acetaminophen after cardiac and noncar-
diac surgery, Figure 3 displays PK profiles of a typical
individual of 6.1 kg after both types of surgery. This
figure shows that maximum concentration is lower after
cardiac surgery compared to noncardiac surgery, while
the through level at 8 hours is higher in patients after
cardiac surgery. Whether these differences also result in
different dose requirements depends on the relationship
between exposure and efficacy and safety parameters in
both populations. This is part of further investigations.
A strength of our analysis is the inclusion of both
acetaminophen and its metabolites. However, as no
study in noncardiac surgery patients investigated all
metabolites, no comparison between cardiac and
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noncardiac pediatric surgery patients can be made
regarding the PK of the metabolites.
Interestingly, oxidation of acetaminophen has been
suggested to be increased in adolescents and adults
with Down syndrome,16 which was not observed in the
current (younger) patient population. In our model, all
parameters were estimated with high accuracy and the
same set of model parameters could be used to predict
acetaminophen and metabolite concentrations without
bias in both subpopulations. The previously observed
findings could be artifacts resulting from a smaller
sample size (4 individuals [mean age, 20.8 [range,
20–21] years) with Down syndrome and 4 individuals
(25.4 [18–32]) without Down syndrome and from per-
forming a noncompartmental analysis. In our study,
we were not able to detect NAPQI and acetaminophen
gluthatione, likely because NAPQI is immediately neu-
tralized by conjugation to gluthathione. When con-
jugation occurs, downstream metabolites will not be
formed and, consequently, cannot be measured. In the
absence of the occurrence of NAPQI in the blood,
no conclusions can be drawn on a possible difference
in the saturation process of NAPQI between children
with and without Down syndrome. As we studied
acetaminophen in the therapeutic range and the above-
mentioned process occurs only with higher doses, we do
not expect that this phenomenon occurred. In addition,
to the best of our knowledge there are no published
reports linking Down syndrome with any differences in
the risk of developing acetaminophen-related hepato-
toxicity.
There are some limitations to our study. In the
absence of recovery of all of the metabolites in urine,
assumptions were necessary to quantify PK parame-
ters of the metabolites. We chose to fix the fraction
eliminated through each pathway based on published
values,25 as there is no reason to assume that con-
tributions of the different metabolic pathways of ac-
etaminophen are altered after cardiac surgery. This
also means that the maturation identified on total
paracetamol clearance is assumed to be the same for
both metabolic pathways. Although model validation
confirmed that the model can accurately describe con-
centrations of acetaminophen and its metabolites with
the estimatedmodel parameters, if the true fractions for
each route deviate from the assumed fractions in chil-
dren after cardiac surgery with cardiopulmonary by-
pass, the elimination clearance and distribution volume
of the metabolites would change. This means that abso-
lute values of the parameters related to the metabolites
should be considered only in the context of the assump-
tions made. Our ability to investigate differences in
acetaminophen PK between children with and without
Down syndrome is not impacted by our assumptions,
as a fractional difference between the groups could still
be tested as a covariate on all model parameters.
Conclusions
In conclusion, we report the PK of acetaminophen
in infants undergoing cardiac surgery. Comparing the
results with those reported in children with noncardiac
surgery, clearance of acetaminophen is decreased while
volume of distribution is increased in children after
cardiac surgery with cardiopulmonary bypass. In this
population, Down syndrome does not impact the PK
of acetaminophen.
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